Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter Cluster Randomized Crossover Study of IVIG Dosing Time in Kawasaki Disease
jRCT1041230181Recruiting
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of immune globulin in Kawasaki disease (KD) (2 arms). Primary endpoint: Fever resolution within 24 hours of IVIG start. Started Mar 2024; status: recruiting.
02
Drugs
immune globulin
03
Conditions
Kawasaki disease (KD)
Beyond the preview
Go deeper on jRCT1041230181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041230181.